The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

A European Union (EU) directive on vitamins and minerals used as ingredients of food supplements with a nutritional or physiological effect (2002/46/EC) was introduced in 2003. Its implications for the use of oral supplements of calcium and vitamin D in the prevention and treatment of osteoporosis were discussed at a meeting organized with the help of the World Health Organization (WHO) Collaborating Center for Public Health Aspects of Rheumatic Diseases (Liège, Belgium) and the support of the WHO Collaborating Center for Osteoporosis Prevention (Geneva, Switzerland). The following issues were addressed: Is osteoporosis a physiological or a medical condition? What is the evidence for the efficacy of calcium and vitamin D in the management of postmenopausal osteoporosis? What are the risks of self-management by patients in osteoporosis? From their discussions, the panel concluded that: (1) osteoporosis is a disease that requires continuing medical attention to ensure optimal therapeutic benefits; (2) when given in appropriate doses, calcium and vitamin D have been shown to be pharmacologically active (particularly in patients with dietary deficiencies), safe, and effective for the prevention and treatment of osteoporotic fractures; (3) calcium and vitamin D are an essential, but not sufficient, component of an integrated management strategy for the prevention and treatment of osteoporosis in patients with dietary insufficiencies, although maximal benefit in terms of fracture prevention requires the addition of antiresorptive therapy; (4) calcium and vitamin D are a cost-effective medication in the prevention and treatment of osteoporosis; (5) it is apparent that awareness of the efficacy of calcium and vitamin D in osteoporosis is still low and further work needs to be done to increase awareness among physicians, patients, and women at risk; and (6) in order that calcium and vitamin D continues to be manufactured to Good Manufacturing Practice standards and physicians and other health care professionals continue to provide guidance for the optimal use of these agents, they should continue to be classified as medicinal products.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    European Commission (2002) Directive 2002/46/EC of the European parliament and of the Council. Official Journal of the European Communities. L183:51–57

    Google Scholar 

  2. 2.

    Melton LJ, Chrischilles EA, Cooper C et al (1992) Perspective: how many women have osteoporosis? J Bone Miner Res 7:1005–1010

    PubMed  Google Scholar 

  3. 3.

    Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Ismail AA, Cooper C, Felsenberg D et al (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 9:206–213

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18[Suppl 3]:185S-189S

  6. 6.

    Schlaich C, Minne HW, Brucker T et al (1998) Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 8:261–267

    CAS  PubMed  Google Scholar 

  7. 7.

    Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800

    CAS  PubMed  Google Scholar 

  8. 8.

    Lips P, Cooper C, Agnusdei D et al (1999) Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire for the European Foundation for Osteoporosis (QUALEFFO). Osteoporos Int 10:150–160

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Pluijm SMF, Dik MG, Jonker C et al (2002) Effects of gender and age on the association of apolipoprotein E ε4 with bone mineral density, bone turnover and the risk of fractures in older people. Osteoporos Int 13:701–709

    Article  Google Scholar 

  10. 10.

    Hall SE, Criddle RA, Comito TL et al (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515

    CAS  PubMed  Google Scholar 

  11. 11.

    Gold DT (2001) The nonskeletal consequences of osteoporotic fractures: psychologic and social outcomes. Rheum Dis Clin North Am 27:255–262

    Google Scholar 

  12. 12.

    Robbins J, Hirsch C, Whitmer R et al (2001) The association of bone mineral density and depression in an older population. J Am Geriatr Soc 49:732–736

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Lyles KW (2001) Osteoporosis and depression: shedding more light upon a complex relationship. J Am Geriatr Soc 49:827–828

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Tosteson ANA, Gabriel SE, Grove MR et al (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Oleksik A, Lips P, Dawson A et al (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392

    CAS  PubMed  Google Scholar 

  16. 16.

    Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515

    CAS  PubMed  Google Scholar 

  17. 17.

    Adachi JD, Ioannidis G, Olszynski WP et al (2002) The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 3:11–18

    Article  PubMed  Google Scholar 

  18. 18.

    Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248–1250

    CAS  PubMed  Google Scholar 

  19. 19.

    Schürch MA, Rizzoli R, Mermillod B et al (1996) A prospective study of socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 11:1935–1942

    PubMed  Google Scholar 

  20. 20.

    Reginster J-Y, Gillet P, Sedrine WB et al (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507–514

    CAS  PubMed  Google Scholar 

  21. 21.

    Autier P, Haentjens P, Bentin J et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373–380

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Cree M, Soskolne CL, Belseck E et al (2000) Mortality and institutionalization following hip fracture. J Am Geriatr Soc 48:283–288

    Google Scholar 

  23. 23.

    Kiebzak GM, Beinart GA, Perser K et al (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217–2222

    Article  PubMed  Google Scholar 

  24. 24.

    Center JR, Nguyen TV, Schneider D et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882

    CAS  PubMed  Google Scholar 

  25. 25.

    Trombetti A, Herrmann F, Hoffmeyer P et al (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13:731–737

    Article  Google Scholar 

  26. 26.

    Cauley JA, Thompson DE, Ensrud KC et al (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Ismail AA, O’Neill TW, Cooper C et al (1998) Mortality associated with vertebral deformity in men and women; results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8:291–297

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445–2448

    CAS  PubMed  Google Scholar 

  29. 29.

    Lippuner K, von Overbeck J, Perrelet R et al (1997) Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 7:414–425

    CAS  PubMed  Google Scholar 

  30. 30.

    International Osteoporosis Foundation (1999) Survey by Helmut Minne, November 1999. http://www.osteofound.org. Cited 3 October 2003

  31. 31.

    Colditz GA, Manson JE, Hankinson SE (1997) The Nurse’s Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6:49–62

    CAS  PubMed  Google Scholar 

  32. 32.

    The Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:496–507

    Article  PubMed  Google Scholar 

  33. 33.

    Häuselmann HJ, Rizzoli R (2003) A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14:2–12

    PubMed  Google Scholar 

  34. 34.

    Heaney RP (1993) Nutritional factors in osteoporosis. Ann Rev Nutr 13:287–316

    Article  CAS  Google Scholar 

  35. 35.

    Välimäki MJ, Kärkkäinen M, Lamberg-Allardt C et al (1994) Exercise, smoking and calcium intake during adolescence and early adulthood as determinants of peak bone mass. BMJ 309:230–235

    PubMed  Google Scholar 

  36. 36.

    Bonjour JP, Carrie AL, Ferrari S et al (1997) Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 99:1287–1294

    CAS  PubMed  Google Scholar 

  37. 37.

    Lehtonen-Veromaa MKM, Möttönen TT, Nuotio IO et al (2002) Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-year prospective study. Am J Clin Nutr 76:1446–1453

    CAS  PubMed  Google Scholar 

  38. 38.

    Boonen S, Vanderschueren D, Cheng XG et al (1997) Age-related (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption. J Bone Miner Res 12:2119–2126

    CAS  PubMed  Google Scholar 

  39. 39.

    Boonen S, Aerssens J, Dequeker J (1996) Age-related endocrine deficiencies and fractures of the proximal femur, II: implications of vitamin D deficiency in the elderly. J Endocrinol 149:13–17

    Google Scholar 

  40. 40.

    Boonen S, Lesaffre E, Dequeker J et al (1996) Relationship between baseline insulin-like growth factor-I and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. J Am Geriatr Soc 44:1301–1306

    CAS  PubMed  Google Scholar 

  41. 41.

    Boonen S, Broos P, Verbeke G et al (1997) Calciotrophic hormones and markers of bone remodeling in age-related (type II) femoral neck osteoporosis: alterations consistent with secondary hyperparathyroidism-induced bone resorption. J Gerontol 52A:M286–M293

    Google Scholar 

  42. 42.

    Reginster J-Y, Deroisy R, Pirenne H et al (1999) High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion. Osteoporos Int 9:121–128

    Article  CAS  PubMed  Google Scholar 

  43. 43.

    Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501

    CAS  PubMed  Google Scholar 

  44. 44.

    McKenna MJ, Freaney R (1998) Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int 8[Suppl 2]:S3–S6

    Google Scholar 

  45. 45.

    Chapuy MC, Preziosi P, Maamer M et al (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439–443

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    Thomas MK, Lloyd-Jones DM, Thadhani RI et al (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783

    CAS  PubMed  Google Scholar 

  47. 47.

    Malabanan AO, Veronikis IE, Holick MF (1998) Redefining vitamin D insufficiency. Lancet 351:805–806

    CAS  Google Scholar 

  48. 48.

    Lips P, Duong T, Oleksik AM et al for the Multiple Outcomes of Raloxifene Evaluation Study Group (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221

    Google Scholar 

  49. 49.

    Pattanaungkul S, Riggs BL, Yergey AL et al (2000) Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D[1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 85:4023–4027

    Google Scholar 

  50. 50.

    Villareal DT, Civitelli R, Chines A et al (1991) Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 72:628–634

    CAS  Google Scholar 

  51. 51.

    Thiébaud D, Burckhardt P, Costanza M et al (1997) Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporos Int 7:457–462

    Article  PubMed  Google Scholar 

  52. 52.

    LeBoff MS, Kohlmeier L, Hurwitz S et al (1999) Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 281:1505–1511

    Article  CAS  PubMed  Google Scholar 

  53. 53.

    Yates AA, Schlicker SA, Suitor CW (1998) Dietary Reference Intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 98:699–706

    Article  CAS  PubMed  Google Scholar 

  54. 54.

    European Commission (1998) Report on osteoporosis in the European Community: action on prevention. Luxembourg Office for Official Publications of the European Communities, p 112

    Google Scholar 

  55. 55.

    European Commission Scientific Committee on Food (2002) Opinion of the Scientific Committee on Food on the tolerable upper intake level of calcium. European Commission, Brussels

  56. 56.

    Hochberg Z, Bereket A, Davenport M et al (2002) Consensus development for the supplementation of vitamin D in childhood and adolescence. Horm Res 5839–5851

  57. 57.

    Holick MF (1998) Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos Int 8[Suppl 2]:S24–S29

    Google Scholar 

  58. 58.

    Lips P, Wiersinga A, Ginkel van FC et al (1988) The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 67:644–650

    Google Scholar 

  59. 59.

    Lips P, Graafmans WC, Ooms ME et al (1996) Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 124:400–406

    Google Scholar 

  60. 60.

    Ooms ME, Roos JC, Bezemer PD et al (1995) Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrin Metab 80:1052–1058

    Article  CAS  Google Scholar 

  61. 61.

    Vieth R, Chan P-CR, MacFarlane GD (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73:288–294

    Google Scholar 

  62. 62.

    European Commission Scientific Committee on Food (2002) Opinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin D. European Commission, Brussels

  63. 63.

    Chapuy MC, Schott AM, Garnero P et al (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab 81:1129–1133

    CAS  PubMed  Google Scholar 

  64. 64.

    Chapuy MC, Pamphile R, Paris E et al (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II Study. Osteoporos Int 13:257–264

    Article  Google Scholar 

  65. 65.

    Chapuy MC, Arlot ME, Duboeuf F et al (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    CAS  PubMed  Google Scholar 

  66. 66.

    Chapuy MC, Arlot ME, Delmas PD et al (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081–1082

    CAS  PubMed  Google Scholar 

  67. 67.

    Meunier PJ, Chapuy MC, Arlot ME et al (1994) Can we stop bone loss and prevent hip fractures in the elderly? Osteoporos Int 4[Suppl 1]:S71–S76

  68. 68.

    Lips P, Chapuy MC, Dawson-Hughes B et al (1999) An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9:394–397

    Article  CAS  PubMed  Google Scholar 

  69. 69.

    Dawson-Hughes B, Harris SS, Krall EA et al (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676

    Google Scholar 

  70. 70.

    Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469–472

    Article  CAS  PubMed  Google Scholar 

  71. 71.

    Meyer HE, Smedshaug GB, Kvaavik E et al (2002) Can vitamin D supplementation reduce the risk of fracture in the elderly? a randomized controlled trial. J Bone Miner Res 17:709–715

    CAS  PubMed  Google Scholar 

  72. 72.

    Shea B, Wells G, Cranney A et al (2002) Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23:552–559

    Article  CAS  PubMed  Google Scholar 

  73. 73.

    Papadimitropoulos E, Wells G, Shea B et al (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569

    Google Scholar 

  74. 74.

    Gillespie WJ, Avenell A, Henry DA et al (2001) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 1:CD000227

    PubMed  Google Scholar 

  75. 75.

    Bischoff HA, Stahelin HB, Dick W et al (2003) Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 18:343–351

    CAS  PubMed  Google Scholar 

  76. 76.

    Pfeifer M, Begerow B, Minne HW et al (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15:1113–1118

    CAS  PubMed  Google Scholar 

  77. 77.

    Lilliu H, Pamphile R, Chapuy M-C et al (2003) Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention. Maturitas 44:299–305

    Article  CAS  PubMed  Google Scholar 

  78. 78.

    European Agency for Evaluation of Medicinal Products (1999) Note for guidance on involutional osteoporosis in women, CPMP/EWP/552/95. European Agency for Evaluation of Medicinal Products, London

  79. 79.

    International Osteoporosis Foundation (2001) Osteoporosis in the European Community: a call to action—an audit of policy developments since 1998. http://www.osteofound.org/publications/pdf.eu_report.pdf. Cited 3 October 2003

  80. 80.

    Juby AG, Davis P (2001) A prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjects. Osteoporos Int 12:617–622

    Article  PubMed  Google Scholar 

  81. 81.

    Dawson-Hughes B, Harris SS, Krall EA et al (2000) Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 72:745–750

    CAS  PubMed  Google Scholar 

  82. 82.

    Romagnoli E, Colangeli I, Minisola S (2000) Awareness, attitudes and opinions on osteoporosis of primary care physicians working in the metropolitan area of Rome: a brief report. Aging Clin Exp Res 12:240–244

    CAS  Google Scholar 

  83. 83.

    Cranney A, Guyatt G, Griffith L et al, the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578

    Article  CAS  PubMed  Google Scholar 

  84. 84.

    Koster JC, Hockeng WHL, Mulder H (1996) Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 51:145–147

    Article  CAS  PubMed  Google Scholar 

  85. 85.

    Masud T, Mulcahy B, Thompson AV et al (1998) Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57:346–349

    CAS  PubMed  Google Scholar 

  86. 86.

    Nieves JW, Komar L, Cosman F et al (1998) Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 67:18–24

    CAS  PubMed  Google Scholar 

  87. 87.

    Sirola J, Kroger H, Sandini L et al (2003) Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study. Calcif Tissue Int 72(6):659

    Article  CAS  PubMed  Google Scholar 

  88. 88.

    Adebowale AO, Cox DS, Liang Z et al (2000) Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials. J Am Nutr Assoc 3:37–44

    Google Scholar 

  89. 89.

    Heaney RP, Barger-Lux MJ (2002) Not all calcium carbonate supplements are equally absorbable. 24th annual meeting ASBMR

Download references

Acknowledgements

This paper reports the conclusions from an international expert meeting organized in Barcelona on 10 November 2002, under the auspices of the World Health Organization Collaborating Center for Public Health Aspects of Rheumatic Diseases (Liège, Belgium) and supported in part by an unrestricted educational grant from Nycomed, Novartis, Shire and Orion Pharma. Dr S. Boonen is senior clinical investigator of the Fund for Scientific Research, Flanders, Belgium (F.W.O–Vlaanderen).

Author information

Affiliations

Authors

Corresponding author

Correspondence to S. Boonen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Boonen, S., Rizzoli, R., Meunier, P.J. et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 15, 511–519 (2004). https://doi.org/10.1007/s00198-004-1621-6

Download citation

Keywords

  • Calcium
  • Fracture prevention
  • Osteoporosis drugs
  • Vitamin D